What's New in Neuroendocrine Tumors (NET): Latest Treatment Advances | 12th OncoWisdom Webinar

What's new in the treatment of Neuroendocrine Tumors (NETs)? Watch the 12th OncoWisdom Webinar, moderated by Dr. Amol Akhade, Medical Oncologist, Fortis Hospital, Mumbai, featuring an expert panel discussion on recent developments in neuroendocrine tumor management. This educational webinar is designed for practicing oncologists, oncology fellows, and healthcare professionals interested in emerging clinical evidence, treatment sequencing, and individualized care for patients with neuroendocrine neoplasms. *Key Topics Covered:* Classification and grading of neuroendocrine tumors (NET G1, G2 and G3) Somatostatin analogues: Octreotide and Lanreotide Peptide Receptor Radionuclide Therapy (PRRT) NETTER-1 and NETTER-2 clinical trials Emerging alpha-emitting radionuclide therapies Targeted therapies, including Everolimus and Cabozantinib The CABINET trial and treatment options for pancreatic and extra-pancreatic NETs Role of chemotherapy and immunotherapy Importance of Ki-67, histopathology and tumor differentiation DOTATATE, DOTANOC and FDG PET imaging Chromogranin A and emerging blood-based biomarkers Observation versus active treatment in selected patients Management of functional and non-functional NETs Advances in lung neuroendocrine tumors *Moderator:* Dr. Amol Akhade Medical Oncologist Fortis Hospital, Mumbai, India *Webinar Series:* 12th OncoWisdom Webinar *About OncoWisdom* The OncoWisdom Circle brings together oncology professionals for scientific discussions, clinical research updates, and evidence-based approaches to cancer treatment. Subscribe to the channel for oncology webinars, expert panel discussions, and updates on emerging cancer treatments. *Disclaimer:* This webinar is intended for professional medical education. Clinical trial findings and expert opinions should be interpreted alongside current clinical guidelines, regulatory approvals, and individual patient circumstances. It is not intended as personalized medical advice. 00:00 Introduction – 12th OncoWisdom Webinar 01:16 NET Classification and Treatment Overview 02:36 Somatostatin Analogues 04:09 PRRT and NETTER Clinical Trials 09:27 Future Directions in PRRT 10:32 Alpha-Emitting Radionuclide Therapy 13:18 Targeted Therapies and CABINET Trial 15:37 Chemotherapy and Immunotherapy 17:18 Expert Panel Discussion 19:23 Clinical Case – NET Grading vs Staging 22:34 Role of Expert Histopathology 27:11 Differentiating NET G3 from NEC 29:37 DOTATATE, DOTANOC and FDG PET Imaging 35:18 Chromogranin A and NETest Biomarkers 40:03 Observation vs Active Treatment 43:10 Functional Neuroendocrine Tumors 47:17 Lung Neuroendocrine Tumors 52:03 NETTER-2 and PRRT Treatment Selection 56:50 Managing Symptoms in NET Patients 59:19 Immunotherapy in Neuroendocrine Carcinoma 1:03:13 Mixed Histology and Emerging Treatments 1:05:00 Novel Therapeutic Targets 1:08:15 Closing Remarks #OncoWisdom #NeuroendocrineTumors #NETTreatment #PRRT #MedicalOncology #CancerResearch